Céline K Stäuble
Biographic Data
| ID | 7975491 |
|---|---|
| NAME | Céline K Stäuble |
| GIVEN NAMES | Céline K |
| FAMILY NAME | Stäuble |
| SIGNATURE | STÄUBLE C K |
| AFFILIATIONS | Solothurner Spitäler |
| ORCID | 0000-0002-2437-4803 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction
Suspected adverse drug reactions (ADRs) during treatment with clozapine often prompt therapeutic drug monitoring (TDM) in clinical practice. Currently, there is no official recommendation for pharmacogenetic (PGx) testing in the context of clozapine therapy. In this case report, we demonstrate and discuss the challenges of interpreting PGx and TDM results highlighting the possibilities and limitations of both analytical methods. A 36-year-old mal…
Case report
We report the case of a 50-year-old male with major depressive disorder (MDD) to illustrate the challenge of finding effective antidepressant pharmacotherapy and the role that the patient's genetic makeup may play. Recent treatment attempts before clinic admission included venlafaxine and fluoxetine. Venlafaxine was discontinued due to lack of response, and subsequently switched to fluoxetine based on pharmacogenotyping of the P-glycoprotein tran…
No prominent works on this page.
Case report
We report the case of a 50-year-old male with major depressive disorder (MDD) to illustrate the challenge of finding effective antidepressant pharmacotherapy and the role that the patient's genetic makeup may play. Recent treatment attempts before clinic admission included venlafaxine and fluoxetine. Venlafaxine was discontinued due to lack of response, and subsequently switched to fluoxetine based on pharmacogenotyping of the P-glycoprotein tran…
Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction
Suspected adverse drug reactions (ADRs) during treatment with clozapine often prompt therapeutic drug monitoring (TDM) in clinical practice. Currently, there is no official recommendation for pharmacogenetic (PGx) testing in the context of clozapine therapy. In this case report, we demonstrate and discuss the challenges of interpreting PGx and TDM results highlighting the possibilities and limitations of both analytical methods. A 36-year-old mal…
Genotype (2 works) · Medicine (2 works) · Psychiatry (2 works) · 5-HTTLPR (1 work) · Adverse drug reaction (1 work) · Adverse effect (1 work) · Allele (1 work) · Biology (1 work) · Bipolar Disorder and Treatment (1 work) · Chemistry (1 work)